Volpara Health Technologies generated its second consecutive quarter of positive net operating cashflow, in a solid 4Q performance, assesses Morgans. Cash receipts of NZ$10m rose by 25% on the previous corresponding period.

Management anticipates cashflow profitability in FY25, though investors should be prepared for a negative 1Q of FY23 due to the timing of annual staff performance payments.

The broker retains its Add rating and $1.21 target.

Sector: Health Care Equipment & Services.

Target price is $1.21.Current Price is $0.79. Difference: $0.42 - (brackets indicate current price is over target). If VHT meets the Morgans target it will return approximately 35% (excluding dividends, fees and charges - negative figures indicate an expected loss).

© 2023 Acquisdata Pty Ltd., source FN Arena